A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience) Meeting Abstract
| Authors: | Baselga, J.; Zamagni, C.; Gomez, P.; Bermejo, B.; Nagai, S.; Melichar, B.; Chan, A.; Mangel, L.; Bergh, J.; Costa, F. P.; Gomez, H. L.; Gradishar, W.; Hudis, C. A.; Rapoport, B.; Roche, H.; Maeda, P.; Huang, L.; Zhang, J.; Schwartzberg, L. |
| Abstract Title: | A phase III randomized, double-blind, trial comparing sorafenib plus capecitabine versus placebo plus capecitabine in the treatment of locally advanced or metastatic HER2-negative breast cancer (resilience) |
| Meeting Title: | 39th ESMO Congress (ESMO 2014) |
| Journal Title: | Annals of Oncology |
| Volume: | 25 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2014 Sep 26-30 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2014-09-01 |
| Language: | English |
| ACCESSION: | WOS:000346901000011 |
| DOI: | 10.1093/annonc/mdu438.5 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA8 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work